6533b858fe1ef96bd12b6025

RESEARCH PRODUCT

Control of Frey's syndrome in patients treated with botulinum toxin type A.

subject

description

Aim: To identify the severity of Frey?s syndrome and its response to botulinum toxin type A. Methods: Minor test was performed in all cases to assess the extent of the affected area, using the contralateral side as control. Severity was assessed according to the proposal of Luna-Ortiz et al. Response was evaluated after 3 and 6 months, and was compared with the basal data. Results: Frey?s syndrome was documented in 38 patients, but only 23 cases accepted the botulinum toxin type A treatment. Severity was moderate in 8 (35%) and severe in 15 (65%) cases. Mean applied dose was 1.41 MU/cm2 in 21 patients (91%), whereas one patient was treated with 10 MU for a 0.8 cm2 affected area (12.5 MU/cm2 ) and another patient with 10 MU for a 0.5 cm2 affected area (20 MU/cm2 ) due to severity of their symptomatology. Average affected area at the beginning was 14.2 cm2 , while after 3 and 6 months of treatment it was 4.1 cm2 and 4.4 cm2 respectively (p0.05). In conclusion, botulinum toxin A remains as the treatment of choice for Frey?s syndrome.